These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30535122)

  • 1. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia.
    Xie F; Mantzarlis K; Malliotakis P; Koulouras V; Degroote S; Koulenti D; Blot S; Boussery K; Van Bocxlaer J; Colin P;
    J Antimicrob Chemother; 2019 Mar; 74(3):667-674. PubMed ID: 30535122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients.
    Dong H; Xie J; Wang T; Chen L; Zeng X; Sun J; Wang X; Dong Y
    Int J Antimicrob Agents; 2016 Sep; 48(3):259-64. PubMed ID: 27474469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant
    Wei X; Zhao M; Xiao X
    J Chemother; 2021 Dec; 33(8):547-553. PubMed ID: 34080519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
    Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.
    Millard J; Pertinez H; Bonnett L; Hodel EM; Dartois V; Johnson JL; Caws M; Tiberi S; Bolhuis M; Alffenaar JC; Davies G; Sloan DJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1755-1762. PubMed ID: 29584861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
    Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
    Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation.
    Wu X; Tang Y; Zhang X; Wu C; Kong L
    Drug Des Devel Ther; 2018; 12():1679-1684. PubMed ID: 29928111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating linezolid dose regimens against methicillin-resistant Staphylococcus aureus based on renal function in populations with different body weight.
    Zuo M; Sun Y; Zhao X; Xu G; Wang N; Chen J; Zhu L; Yang W; Zhao M
    J Clin Pharm Ther; 2022 Dec; 47(12):2162-2169. PubMed ID: 36053892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective.
    Barrasa H; Soraluce A; Usón E; Sainz J; Martín A; Sánchez-Izquierdo JÁ; Maynar J; Rodríguez-Gascón A; Isla A
    Int J Infect Dis; 2020 Apr; 93():329-338. PubMed ID: 32112965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus.
    Docobo-Pérez F; López-Rojas R; Domínguez-Herrera J; Jiménez-Mejias ME; Pichardo C; Ibáñez-Martínez J; Pachón J
    J Antimicrob Chemother; 2012 Aug; 67(8):1961-7. PubMed ID: 22532466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections.
    Blackman AL; Jarugula P; Nicolau DP; Chui SH; Joshi M; Heil EL; Gopalakrishnan M
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33257446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
    Collins CD; Schwemm AK
    Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing vancomycin in the super obese: less is more.
    Crass RL; Dunn R; Hong J; Krop LC; Pai MP
    J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.